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abstract
 
Metabotropic 
 
g
 
-aminobutyric acid (GABA) receptors were studied in amphibian retinal ganglion
cells using whole cell current and voltage clamp techniques. The aim was to identify the types of receptor present
and their mechanisms of action and modulation. Previous results indicated that ganglion cells possess two iono-
tropic GABA receptors: GABA
 
A
 
R and GABA
 
C
 
R. This study demonstrates that they also possess two types of metabo-
tropic GABA
 
B
 
 receptor: one sensitive to baclofen and another to 
 
cis
 
-aminocrotonic acid (CACA). The effects of
these selective agonists were blocked by GDP-
 
b
 
-S. Baclofen suppressed an 
 
v
 
-conotoxin–GVIA-sensitive barium cur-
rent, and this action was reversed by prepulse facilitation, indicative of a direct G-protein pathway. The effect of
baclofen was also partially occluded by agents that influence the protein kinase A (PKA) pathway. But the effect of
PKA activation was unaffected by prepulse facilitation, indicating PKA acted through a parallel pathway. Calmodu-
lin antagonists reduced the action of baclofen, whereas inhibitors of calmodulin phosphatase enhanced it. Antag-
onists of internal calcium release, such as heparin and ruthenium red, did not affect the baclofen response. Thus,
the baclofen-sensitive receptor may respond to influx of calcium. The CACA-sensitive GABA receptor reduced
current through dihydropyridine-sensitive channels. Sodium nitroprusside and 8-bromo-cGMP enhanced the ac-
tion of CACA, indicating that a nitric oxide system can up-regulate this receptor pathway. CACA-sensitive and ba-
clofen-sensitive GABA
 
B
 
 receptors reduced spike activity in ganglion cells. Overall, retinal ganglion cells possess
four types of GABA receptor, two ionotropic and two metabotropic. Each has a unique electrogenic profile, pro-
viding a wide range of neural integration at the final stage of retinal information processing.
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introduction
 
The retina has emerged as a model system for the study
of 
 
g
 
-aminobutyric acid (GABA)
 
1
 
 receptors. It possesses
a diversity of GABA
 
A
 
 receptors (GABA
 
A
 
R) (Greferath et
al., 1995), at least two types of GABA
 
B
 
 receptor (GABA
 
B
 
R)
(Matthews et al., 1994; Tian and Slaughter, 1994), and
a GABA
 
C
 
 receptor (GABA
 
C
 
R) (Cutting et al., 1991).
These receptors produce a variety of electrogenic ef-
fects including the ionotropic increase in chloride con-
ductance and the metabotropic modulation of a cal-
cium conductance and activation of a putative potas-
sium conductance. The ability of GABA to produce this
multiplicity of effects permits a precise and varied inte-
gration of synaptic information.
While a plethora of GABA receptors have been iden-
tified in retina, often they have been discretely local-
ized to small groups of neurons. For example, in white
perch retina the GABA
 
C
 
R has been described in a rod-
driven horizontal cell (H4) (Qian and Dowling, 1993),
while in catfish retina this receptor was found in cone-
driven, but not rod-driven, horizontal cells (Dong et
al., 1994; Takahashi et al., 1994). The baclofen-sensitive
GABA
 
B
 
R has been identified in fish ganglion cells but
was not seen in fish horizontal or bipolar cells (Bindo-
kas and Ishida, 1991). In one type of goldfish bipolar
cell a 
 
cis
 
-aminocrotonic acid (CACA)-sensitive, but not
the baclofen-sensitive, GABA receptor was detected
(Matthews et al., 1994). This restricted expression fits a
model in which GABARs are precisely localized so that
each receptor subtype is associated with particular neu-
rons. The implication is that there is a functional corre-
lation between receptor properties, such as conduc-
tance and kinetics, and the physiology of the neuron.
In this context, Pan and Lipton (1995) reported that
the GABA
 
C
 
R found in rat bipolar cells produced a
smaller and slower current than the GABA
 
A
 
R. It is
tempting to conclude that there is a good match be-
tween this receptor and the relatively slow and small re-
sponses of the rod pathway.
An alternative model of GABA receptor diversity is
that multiple GABARs may be localized in one cell and
thereby expand the inhibitory capability of that neu-
 
Dr. Jian Zhang’s present address is Department of Ophthalmology
and Visual Science, University of Texas Medical Center, Houston, TX
77030.
Address correspondence to Dr. Malcolm Slaughter, SUNY, Depart-
ment of Biophysics, 120 Cary Hall, Buffalo, NY 14214. Fax: 716-829-
2415; E-mail: mslaught@ubmed.buffalo.edu
 
1
 
Abbreviations used in this paper:
 
 CACA, 
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-aminobutyric acid; GDP-
 
b
 
-S, guanosine 5
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phate); HVA, high voltage–activated.
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ron. If present, this confluence of GABA receptor sub-
types could be particularly important in retinal gan-
glion cells, the recipients of powerful GABAergic input
from amacrine cells and the final integrators of retinal
information. Therefore, we examined retinal ganglion
cells to determine their complement of GABA recep-
tors. We previously reported that amphibian ganglion
cells possess two types of ionotropic GABA receptor:
GABA
 
A
 
 and GABA
 
C
 
 (Zhang and Slaughter, 1995). We
find that these neurons also contain two types of me-
tabotropic GABA receptor, one sensitive to baclofen
and the other to CACA. Thus, ganglion cells possess ev-
ery type of GABA receptor currently identified. Through
these different receptors, GABA regulates chloride and
potassium conductances and modulates voltage-depen-
dent calcium conductances. This permits a graded level
of inhibition by parallel deployment of different con-
ductance mechanisms. The GABA receptors can be dif-
ferentially modulated by the internal or external envi-
ronment of the ganglion cell, indicating that the bal-
ance of receptor inhibition can be tuned.
 
materials and methods
 
Experiments were performed in aquatic tiger salamander (
 
Am-
bystoma tigrinum
 
) retinal slice preparation, which has been de-
scribed in detail previously (Werblin, 1978; Wu, 1987). In brief,
the animal was decapitated, double pithed, and the eye was enu-
cleated. The cornea, lens, and vitreous were removed, exposing
the retina. The retina was separated from the pigment epithe-
lium and positioned, photoreceptor side down, on filter paper.
The retina and filter paper were sectioned into 200–300-
 
m
 
m
thick slices. These sections were placed on their sides in a perfu-
sion chamber and positioned on the stage of an upright micro-
scope fitted with Hoffman modulation optics. The retinal layers
and individual neurons could be observed while a microelec-
trode was positioned for whole cell recording. Low resistance
electrodes (
 
,
 
5 M
 
V
 
) were used to form gigaseals. Recordings
were obtained from neurons in the ganglion cell layer, a somatic
layer that Lukasiewicz and Werblin (1988) found to be almost ex-
clusively populated by ganglion cells. In some cases the neurons
were stained with Lucifer yellow (0.05% added to pipette solu-
tion) and retrospectively identified as ganglion cells.
A few experiments were performed on isolated ganglion cells.
A similar dissection procedure and standard dissociation proce-
dures were employed, as detailed previously (Pan and Slaughter,
1995).
Whole cell pipette solution consisted of (in mM): 106 K-glu-
conate, 5 NaCl, 2 MgCl
 
2
 
, 5 EGTA, and 5 HEPES, buffered to pH
7.4 with KOH. To reduce calcium channel run-down, the pipette
solution also contained an “ATP-regenerating cocktail” consist-
ing of 4 mM ATP, 20 mM phosphocreatine, and 50 U/ml creat-
ine phosphokinase. In experiments to study the CACA-sensitive
GABA receptor, the ATP-regenerating system was replaced with 4
mM ATP and 0.3 mM GTP. At the recommendation of one re-
viewer, a few experiments were performed using nystatin perfo-
rated patches. In these cases, the same internal solution was used
without the ATP-regenerating medium.
Both voltage steps and ramps were used to evoke currents.
Since the barium currents that we measured were sustained and
showed very little inactivation over this time course, we found
that results using the step and ramp were similar. For conve-
nience, ramp data were most often obtained. The figures in this
paper display the original data and are not corrected for elec-
trode tip potential or series resistance. The cells had high input
resistances so leak subtraction was not necessary. The tip poten-
tial was measured for each pipette solution (Neher, 1992), and
the correction factor is mentioned in 
 
results
 
, particularly where
reversal potential measurements are presented. The amplifier
did not have series resistance compensation. Except for perfo-
rated patch recordings, access resistance was generally between 6
and 15 M
 
V
 
. This resulted in an offset in the peak barium cur-
rents. However, since we were monitoring sustained currents and
examining these currents over a wide range of potentials, this off-
set did not significantly influence our results. In a few cases,
where a large shift occurred, the data were discarded. When both
tip potential and series resistance voltage offsets were subtracted,
the barium current was calculated to peak near 
 
1
 
10 mV. This in-
formation was not a topic of this paper, so these calculations were
not routinely done for each cell and the raw data is shown with-
out these corrections. Voltage clamp experiments were per-
formed using an Axoclamp 2A amplifier in continuous voltage
clamp mode and PCLAMP software on a Gateway 486 computer
equipped with a Labmaster A/D board. Analysis was performed
employing PCLAMP, EXCEL, and Origin software.
Control amphibian Ringer’s solution consisted of (in mM):
111 NaCl, 2.5 KCl, 1.8 CaCl
 
2
 
, 1 MgCl
 
2
 
, 10 dextrose, and HEPES
buffered to pH 7.8 and oxygenated. When calcium currents were
studied in isolation, 10 mM BaCl
 
2
 
 and 40 mM tetraethyl ammo-
nium chloride (TEA
 
?
 
Cl) replaced equimolar NaCl in the extra-
cellular medium. Tetrodotoxin (1 
 
m
 
M) was used to block sodium
currents. Application of 25 
 
m
 
M CdCl
 
2
 
 suppressed most of the in-
ward current under these conditions, indicating that most, if not
all, of the observed current arose from calcium channels. Control
and drug containing solutions were applied through a gravity fed
system to a manifold in connection with the perfusion chamber
containing the retinal slice. Valves controlled drug application,
and there was a delay of 
 
z
 
10 s due to exchange time of the sys-
tem. Alternatively, drugs were applied through a puff pipette po-
sitioned at the edge of the retina near the cell of interest. In this
case, Ringer’s solution was still constantly applied to the retinal
slice. When antagonists were tested, they were applied first, then
after 30–60 s agonist was applied with antagonist. Generally, one
cell was recorded in each retinal slice to avoid residual drug ef-
fects. Drug effects described in this paper are steady-state values,
usually obtained 30–60 s after drug application.
The drug concentrations required to evoke effects in the slice
preparation were often higher than anticipated, indicating that
there was a diffusion or uptake barrier. For example, 100 
 
m
 
M
GABA had only a small effect in the slice preparation, although it
produced a near maximal effect when applied to isolated gan-
glion cells (Pan and Slaughter, 1995). This was true for glutamate
as well (Shen and Slaughter, unpublished observations). There-
fore, there is probably a disparity between the dose applied and
the effective drug concentration at the receptor. This phenome-
non has been noted in retinal slice studies from other laborato-
ries. Also, during the course of these studies we noted a decrease
in the response to baclofen and to 
 
cis
 
-aminocrotonic acid. Whether
this represented a seasonal change or other effect was unclear. A
series of initial experiments were performed using 100 
 
m
 
M ba-
clofen, later 50 
 
m
 
M baclofen was used. In 
 
results
 
, the average ef-
fect of 100 
 
m
 
M baclofen is reported to be greater than the effect
of 50 
 
m
 
M, but this is probably due to the time periods when the
studies were completed. Some experiments compare the effects
of second messenger antagonists with the average effect of 100 or
50 
 
m
 
M baclofen. These antagonist experiments were performed
in periods that overlapped the experiments from which the aver- 
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age data were obtained, and therefore represent ganglion cell
populations with appropriate control responses. In CACA experi-
ments, 5 
 
m
 
M doses produced nearly 50% suppression in early ex-
periments (winter), but only about 20% suppression in later ex-
periments (summer). Again, this may have been due to seasonal
changes or other factors. When comparing data between experi-
ments, we only contrasted effects measured at the same time pe-
riod (usually the same day or week). All statistical data are pre-
sented as means 
 
6
 
 SEMs.
SR95531, 2-hydroxysaclofen, nifedipine, nimodipine, trifluo-
perazine, KN-62, forskolin, H-9, Rp-cAMP, microcystin, calmida-
zolium, ruthenium red, heparin, N
 
G
 
-monomethyl-
 
l
 
-arginine, and
sodium nitroprusside were purchased from Research Biochemi-
cals, Inc. (Natick, MA). CACA was obtained from Tocris Cookson
(St. Louis, MO). Cyclosporin A was obtained from Calbiochem
Corp. (San Diego, CA). CGP35348 and baclofen were gifts from
Ciba-Geigy (Basel, Switzerland). All other chemicals were ob-
tained from Sigma Chemical Co. (St. Louis, MO).
 
results
 
GABA-regulated Currents in Ganglion Cells
 
The effect of GABA was tested on ganglion cells in the
retinal slice preparation by holding neurons at 
 
2
 
70 mV
and then stepping them to various potentials between
 
2
 
120 and 
 
1
 
60 mV, as illustrated in the left column of
Fig. 1. Under control conditions (Fig. 1 
 
A
 
), ganglion
cells exhibited two prominent currents: a fast inward
sodium current (that was truncated in this figure) and
a large outward potassium current. The effects of a lo-
calized puff of GABA (Fig. 1 
 
B
 
) and recovery (Fig. 1 
 
C
 
)
are shown, and the I-V relationships under all three
conditions are illustrated (Fig. 1 
 
D
 
). The currents were
measured at a time corresponding to the peak of the
GABA induced current in Fig. 1 
 
B
 
. The difference cur-
rent (drug minus control), representing the isolated
GABA current, is plotted in Fig. 1 
 
E
 
. This figure shows
that the GABA-induced current is fairly linear between
 
2
 
100 and 
 
2
 
20 mV, and reverses near 
 
2
 
60 mV. Cor-
recting for the tip potential indicates that this current
reverses at 
 
2
 
69 mV, close to the estimated chloride re-
versal potential (
 
2
 
72 mV). Numerous reports indicate
that a large portion of this chloride current is due to ac-
tivation of GABA
 
A
 
Rs (Miller et al., 1981; Ishida and Co-
hen, 1988; Cohen et al., 1989; Müller et al., 1992;
Lukasiewicz and Werblin, 1994). We found that GABA-
activated chloride current in salamander ganglion cells
results from activation of both GABA
 
A
 
 and GABA
 
C
 
 re-
ceptors (Zhang and Slaughter, 1995).
A notch is apparent in the I-V curve (Fig. 1 
 
E
 
) in the
region where high voltage–activated (HVA) calcium
currents might arise. This suggests that an additional
effect of GABA is to suppress a voltage-activated cal-
cium conductance, resulting in a reduction in an out-
ward potassium conductance. The calcium current was
blocked to test this hypothesis. When a protocol similar
to that in Fig. 1 
 
E
 
 was used in the presence of 100 
 
m
 
M
external cadmium (this recording is from a different
neuron than the one in Fig. 1, 
 
A
 
–
 
E
 
), the GABA I-V
curve was relatively linear and lacked the notch (Fig. 1
 
F
 
). The data support the supposition that the notch was
due to the GABA-induced reduction of a calcium-acti-
vated outward current. Ensuing experiments indicate
that GABA does suppress calcium channel currents.
 
Receptor Modulation of Calcium Currents
 
In a number of systems, a baclofen-sensitive GABA
 
B
 
R
has been associated with the down-regulation of cal-
Figure 1. GABA induced currents in retinal ganglion cells. This
shows the current responses of a ganglion cell to voltage steps un-
der control conditions (A), during 200-ms puffs of 500 mM GABA
from a pipette near the proximal edge of the retina (B), and after
cessation of GABA application (C). The current at the end of the
GABA puff was plotted for each voltage under all three conditions
(D), and the GABA current was calculated by subtracting the con-
trol currents from the GABA currents, and this is plotted (E).
When the calcium current was blocked by 100 mM cadmium, then
GABA puffs produced currents that did not show a notch in the I-V
curve (F). Recordings A–E were obtained from the same cell; re-
sults shown in F were from another neuron. Recordings were ob-
tained from ganglion cells in the retinal slice preparation super-
fused with normal Ringer’s solution. Cells were clamped to 270
mV and then stepped to voltages ranging from 2120 mV to 160
mV in 15-mV increments as illustrated. Symbols in panels E–F indi-
cate the currents observed at each voltage step, the line connect-
ing these data points was drawn by eye. 
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cium currents. In retina, this has been reported in a
subset of amphibian bipolar cells (Maguire et al., 1989)
and in goldfish ganglion cells (Bindokas and Ishida,
1991). We therefore examined the effect of baclofen
on calcium channel current in amphibian ganglion
cells. The measurement of calcium channel current re-
quired a modified Ringer’s solution, which contained
10 mM barium, 40 mM TEA-Cl, and was nominally cal-
cium free. Under these conditions we observed an
HVA, relatively sustained inward current that was
blocked by 100 
 
m
 
M external cadmium (data not
shown). In all these experiments, barium was the charge
carrier. Since this current was relatively noninactivat-
ing, we found that similar data were obtained using ei-
ther voltage steps or ramps.
Baclofen suppressed a portion of the HVA barium
current in ganglion cells (Fig. 2). The neuron was held
at 
 
2
 
70 mV, stepped to 
 
2
 
120 mV, and then the voltage
was ramped to 
 
1
 
60 mV in 1 s. This paradigm evoked an
inward barium current (Fig. 2 
 
A1
 
) that was suppressed
approximately 30% by 100 
 
m
 
M baclofen (Fig. 2 
 
A2
 
).
Adding 2-hydroxysaclofen (1 mM), an antagonist of ba-
clofen-sensitive GABA receptors (Kerr et al., 1988), re-
stored the inward current close to its control value (Fig.
2 A3). The lower three panels, taken from recordings
of another ganglion cell, show that picrotoxin, an an-
tagonist of both GABAARs and GABACRs, did not block
the effect of baclofen on the HVA barium current. In
experiments on 73 cells, 50 mM baclofen reduced the
HVA current by 29 6 1% (mean 6 SEM), while in an-
other 22 ganglion cells 100 mM baclofen reduced the
barium current by 40 6 3% (see materials and meth-
ods regarding this difference). In the presence of 100
mM picrotoxin, 100 mM baclofen reduced the barium
current by 44 6 3% (n 5 6), indicating that picrotoxin
did not reduce baclofen’s action. This pharmacology
leads to the conclusion that amphibian ganglion cells
possess a baclofen-sensitive GABABR that can down-reg-
ulate HVA calcium currents.
In previous studies (Tian and Slaughter, 1994),
CGP35348 was found to block baclofen but 2-hydroxy-
saclofen did not. In the present experiments, both were
effective baclofen antagonists. The difference is that in
the prior experiments the concentration of 2-hydroxy-
saclofen was 100 mM while in the present experiments
that concentration was raised to 1 mM.
To determine if ganglion cells possessed another
GABA receptor, we applied GABA in the presence of
antagonists of the GABAAR, GABACR, and the ba-
clofen-sensitive GABABR. Since 2-hydroxysaclofen is a
weak and competitive antagonist of baclofen-sensitive
GABABRs, we sometimes chose to saturate the baclofen-
sensitive receptor instead of blocking it. When GABA
was applied in the presence of SR95531, picrotoxin,
and baclofen, it was still able to produce an additional
suppression of the barium current (Fig. 3 A). In nine
cells tested in this manner, GABA reduced the barium
current by 11 6 2%. Another GABAR has been identi-
Figure 2. Baclofen reduces a
voltage-activated barium cur-
rent. The voltage was ramped
from 2120 to 160 mV in 1 s.
The barium current was iso-
lated and enhanced by replac-
ing extracellular calcium with
10 mM barium and adding 40
mM TEA (equimolar replace-
ment of NaCl). The top three
panels show that 100 mM ba-
clofen reduced the barium cur-
rent, and the effect of baclofen
was reversed by 1 mM 2-hydrox-
ysaclofen. The lower set of pan-
els confirms that 100 mM picro-
toxin did not block the effect of
baclofen.49 Zhang et al.
fied in goldfish retina and shown to down-regulate
HVA calcium channels in bipolar cells (Matthews et al.,
1994). This has been proposed as a novel type of
GABABR. It can be identified pharmacologically by its
sensitivity to low micromolar concentrations of CACA
and its insensitivity to bicuculline, SR95531, picrotoxin,
baclofen, or 2-hydroxysaclofen.
This receptor is also present in amphibian ganglion
cells. A low micromolar concentration of CACA was
able to reduce the HVA barium current in a reversible
manner (Fig. 3 B). CACA produced a 40% decrease in
the barium current in this neuron. We saw no evidence
that low doses of CACA changed the conductance of
the cell (monitored at negative potentials where volt-
age-dependent channels were not activated), although
at much higher concentrations it can activate the
GABAAR as well as the GABACR in these cells (Zhang
and Slaughter, 1995). The lower set of panels, taken
from another ganglion cell, show that the effect of
CACA persisted when it is applied in the presence of pi-
crotoxin, which blocked the GABAA&CRs, and 2-hydroxy-
saclofen, which blocked the baclofen-sensitive GABABR.
As noted by Matthews et al. (1994), CACA effects were
robust when the inside of the cell was dialyzed with
GTP. With 0.3 mM GTP in the pipette, CACA reduced
the barium current by a mean of 46 6 5% in nine cells.
When GTP was not included in the pipette solution,
CACA produced a smaller reduction in the barium cur-
rent of 23 6 2% in 14 cells. This is different than the
action of baclofen, which did not depend on GTP dialy-
sis. Without GTP dialysis the recovery after CACA treat-
ment was poor. All subsequent CACA experiments de-
scribed in this report were performed using GTP dialysis.
The GABA experiments in Fig. 3 did not include GTP.
Since different internal solutions were used in re-
cording baclofen-sensitive and CACA-sensitive currents,
nystatin perforated patch recordings were used to com-
pare the actions of baclofen, CACA, and GABA while
limiting the effects of cell dialysis. High concentrations
were used to produce maximal responses to each ago-
nist (50 mM CACA, 100 mM baclofen, and 200 mM
GABA). The retina slice was pretreated and continu-
ously superfused with picrotoxin (200 mM) to avoid the
effects on ionotropic GABA receptors. In five cells, ba-
clofen was found to reduce the barium current by a
mean of 28% (from a control value of 1,028 6 169 pA
to 708 6 109 pA); CACA reduced the current by 9% (to
924 6 135 pA); GABA reduced the current by 46% (to
534 6 82 pA). The response to each agonist was statisti-
cally significant (P , 0.05, Wilcoxin’s signed-ranks test).
The ionotropic GABACR is sometimes referred to as
CACA-sensitive because CACA can be more effective at
activating the GABACR than the GABAAR (Feigenspan
et al., 1993; Qian and Dowling, 1993; Pan and Lipton,
1995). We previously reported that high concentra-
tions of CACA were needed to stimulate the GABACR,
and these concentrations also activated the GABAAR
(Zhang and Slaughter, 1995). This is in contrast to the
receptor identified in Fig. 3, which is sensitive to low
micromolar concentrations of CACA. To avoid confu-
sion with reports describing CACA sensitivity of the
GABACR or GABAAR, we refer to this receptor as the
CACA-sensitive GABABR (GABAB-CACAR).
Baclofen’s Action on Different Types of Calcium Channels
Calcium channel blockers were employed to evaluate
the characteristics of the currents regulated by ba-
clofen or CACA. The left side of Fig. 4 shows examples
of ramp-elicited barium currents in the presence of ba-
clofen alone, the blocker alone, and the combination
Figure 3. Ganglion cells possess a CACA-sensitive GABA recep-
tor. (A) There is a GABA effect on barium current not due to the
GABAAR, the baclofen sensitive GABABR, or the GABACR. When
these receptors were blocked (GABAAR and GABACR) or saturated
(GABABR), GABA still caused a reversible reduction in the voltage
activated barium current. (B) Low doses of CACA reduced the bar-
ium current. (C) This effect of CACA was not blocked by a combi-
nation of antagonists that together block the GABAAR, GABACR,
and the baclofen-sensitive GABABR.50 Retinal GABA Receptors
of baclofen with the channel blocker. 19 ganglion cells
were used to test the effects of two L-type calcium chan-
nel blockers: nimodipine and nifedipine. The effect of
50 mM baclofen alone was tested in 14 of the 19 cells
and found to reduce the barium current by 21 6 2%.
In the 19 cells, 50 mM nifedipine or nimodipine was ap-
plied. This is a concentration found to block baclofen’s
effect on L-type calcium channels in bipolar cells in the
same preparation (Maguire et al., 1989). These dihy-
dropyridines reduced the barium current by 17 6 2%.
In the presence of nifedipine or nimodipine, baclofen
reduced the calcium current in these 19 cells by an ad-
ditional 22 6 2%. Thus, baclofen produced approxi-
mately the same percent suppression of the calcium
current whether the dihydropyridine channel blockers
were present or not. If baclofen had no effect on the
L-type calcium current, then the percentage suppres-
sion by baclofen should be greater in the presence of
these blockers. That is, if these two effects were inde-
pendent they should be additive. On average, the per-
cent suppression by baclofen was slightly greater in the
presence of the blockers, but this was not statistically
significant. Since the blockers reduced the calcium cur-
rent by 17% on average, an additive effect would only
alter the percent suppression by baclofen from a mean
suppression of 21% to a mean suppression of 25%
(compared to the observed mean suppression of 22%).
Therefore, we can conclude that baclofen does not act
primarily on L-type channels, although we cannot ex-
clude a small modulation of L-type calcium channels.
The N-type channel blocker, v-conotoxin–GVIA, had
a much larger effect on both the calcium current and
baclofen’s action (Fig. 4, bottom). In eight cells, v-cono-
toxin reduced the barium current by 57 6 7%. In the
presence of v-conotoxin, 50 mM baclofen produced
only a 14 6 3% suppression of the remaining reduced
barium current. Of the eight cells used in these experi-
ments, seven had been previously tested with baclofen
alone. Baclofen had produced a mean barium current
suppression of 37 6 2%. If baclofen acted exclusively
on non–N-type calcium channels, it would be expected
to suppress 86% of the remaining calcium current in
the presence of v-conotoxin. If v-conotoxin-GVIA is
acting selectively, this indicates that a large fraction of
the baclofen effect is on the N-type channel.
The CACA-sensitive GABAB Receptors Act on L-type 
Calcium Channels
In contrast to the effect of the GABAB-BACLOFENR, the
GABAB-CACAR appears to act predominantly at the dihy-
dropyridine-sensitive calcium channel (Fig. 5). The top
row in this figure shows a recording from one ganglion
cell in which 50 mM nimodipine reduced the voltage-
activated barium current. In the presence of nimo-
dipine, 5 mM CACA had little additional effect. After
washout and recovery of the barium current, CACA
alone was able to reduce the barium current. The re-
duction by CACA was similar to that produced by nimo-
dipine. A summary of data is charted in the lower por-
Figure 4. The GABAB-BACLOFENR
suppresses a v-conotoxin–GVIA-
sensitive calcium channel. The
upper left panel in A shows that
baclofen reversibly reduces bar-
ium current (1 5 control; 2 5
baclofen; 3 5 recovery). The ad-
jacent panel in A, from the same
cell, illustrates that 50 mM nimo-
dipine (2) reduces the control
barium current (1), but 50 mM
baclofen in the presence of nimo-
dipine (3) further reduces the
current. A summary of the results
is charted in the upper right
panel. In total 19 neurons were
tested, but in only 14 of the 19
was baclofen alone tested. The
bottom row illustrates similar
studies performed using v-con-
otoxin-GVIA (v-CgTx) (2), an
N-type  calcium channel blocker,
followed by application of 50
mM baclofen in the presence of
v-CgTx (3). A summary of data
on eight neurons appears in
lower right panel. Seven of the
eight were tested with baclofen
alone.51 Zhang et al.
tion of Fig. 5. The CACA alone data in this chart are
drawn from our initial study of nine ganglion cells in
which 5 mM CACA suppressed a mean of 46 6 5% of
the barium current. In a different set of ten ganglion
cells, 50 mM nimodipine reduced the barium current
by 25 6 3%. In these ten neurons, after nimodipine re-
duced the barium current, CACA in the presence of ni-
modipine produced an additional barium current re-
duction of 9 6 3%. All recordings were performed with
0.3 mM GTP in the patch electrode.
GABABR Effects on Ganglion Cell Spike Activity
A simple method of analyzing the influence of metabo-
tropic GABA receptors on ganglion cells is to use cur-
rent clamp recordings. The protocol for these experi-
ments was to record from neurons in the ganglion cell
layer under whole cell current clamp and evoke spike
activity by applying 300-ms positive current pulses un-
der control conditions and during application of GABA
agonists (see Fig. 7 A). Both baclofen and CACA pro-
duced modest reductions in ganglion cell spike activity
(Fig. 6 A). In experiments on 16 cells, baclofen re-
duced the number of spikes in every case, with a mean
reduction of 28 6 12% (P , 0.01, Wilcoxin’s signed-
ranks test). CACA reduced spike number in all twelve
cells tested, with a mean reduction of 22 6 8% (P ,
0.01, Wilcoxin’s signed-ranks test). We also noted that
both agonists produced spike broadening of approxi-
mately 30%. Calcium-activated potassium channels al-
ter spike frequency (Hille, 1992), which probably ex-
plains these GABAB receptor actions. This assumption
is supported by the observation that cadmium, a cal-
cium channel antagonist, produced effects that were
very similar to CACA or baclofen. An example is shown
in Fig. 6 B, which compares the effects of cadmium and
baclofen on responses to current injections in a gan-
glion cell. Liu and Lasater (1994a) found that dopa-
mine produced a similar, though more powerful, sup-
pression of spike activity in turtle ganglion cells.
Baclofen and CACA Act through G-protein Pathways
Transmitter-receptor systems that modulate voltage-
activated calcium channels are generally metabotropic
and blocked by agents that interfere with the G-protein
cascade. This was tested using guanosine 59-O-(2-thio-
diphosphate) (GDP-b-S), which blocks G-protein–medi-
ated pathways (Fig. 7). The protocol was similar to previ-
ous experiments except that 1 mM GDP-b-S was included
in the pipette. A calcium current was periodically evoked,
then baclofen or CACA was applied. The graphs show
the peak currents before, during, and after prolonged
drug application. Baclofen and CACA produced only a
slight reduction in the current. Representative cur-
rents, measured at the points marked by numbers on
the graphs, are shown. Similar results were obtained in
six other ganglion cells, indicating that both CACA and
baclofen required functional G-protein systems.
Baclofen’s Second Messenger Pathway
The effect of baclofen was reversed by prepulse facilita-
tion. These experiments were performed in isolated
Figure 5. The GABAB-CACAR
modulates a dihydropyridine-
sensitive barium current. The
top trace shows recordings from
one ganglion cell in which the
barium current was evoked by a
voltage ramp. The current was
suppressed by 50 mM nimo-
dipine or 5 mM CACA. In the
presence of nimodipine, the ef-
fect of CACA was occluded.
The chart shows data on a pop-
ulation of nine ganglion cells in
which CACA suppressed the
barium current and another set
of ten ganglion cells in which
nimodipine reduced the bar-
ium current and largely oc-
cluded the action of CACA.52 Retinal GABA Receptors
cells. The protocol was to activate high voltage–acti-
vated calcium channels by depolarizing the cell to 110
mV, from a holding potential of 270 mV. Then the cell
was prepulsed to 1100 mV, then again clamped to 110
mV. Fig. 8 shows superimposed currents obtained un-
der control conditions and in the presence of baclofen.
High concentrations of baclofen were required to acti-
vate the GABA receptor in the isolated cell prepara-
tion. The reason for this is currently being investigated.
However, the effects of baclofen in isolated cells were
similar to those found in the slice, both in terms of
pharmacology (2-hydroxysaclofen sensitivity) and elec-
trogenic action. Under control conditions, the barium
current was of similar magnitude before and after the
prepulse. But, in the presence of baclofen, the barium
current was much larger after the prepulse (arrows).
The peak of the barium current in baclofen, after the
prepulse, was similar to the magnitude of the barium
current before baclofen application. Prepulse facilita-
tion has been reported for a number of metabotropic
transmitter systems, including the GABABR. It has been
suggested the phenomenon is indicative of a direct
G-protein modulation of the calcium channel (Boland
and Bean, 1993; Campbell et al., 1995).
The effect of baclofen was reduced, but not elimi-
nated, by a variety of agents that interfere with the pro-
tein kinase A (PKA) pathway. Examples of the effects of
these agents and a summary of the data are shown in
Fig. 9. Except for forskolin, all drugs were dialyzed into
the cell by including them in the pipette solution.
Therefore, the effects of baclofen during dialysis of
these drugs were compared to effects of baclofen on a
control population of neurons. The control data used,
presented above, are that 50 mM baclofen reduced the
HVA calcium current by a mean of 29% (n 5 73),
whereas 100 mM baclofen reduced this current by 40%
(n 5 22). When H-7, a protein kinase inhibitor, was di-
alyzed into 11 cells, the effect of 100 mM baclofen was
reduced to approximately half the normal magnitude
(19 6 3%). But Rp-cAMP, a specific blocker of protein
kinase A, had little effect on the response to baclofen.
Figure 6. Effects of CACA and baclofen on ganglion cell spike
activity. (A) Ganglion cell spiking was elicited by brief (300 ms)
current injections. Both baclofen and CACA decreased spike activ-
ity. (B) The reduction in spike activity produced by baclofen was
duplicated by cadmium.
Figure 7. GDP-b-S blocks the effects of CACA and baclofen.
Whole cell recordings were performed while including 1 mM
GDP-b-S in the pipette solution. The graphs show the peak barium
current measured at fixed intervals before, during, and after drug
application.53 Zhang et al.
In the presence of Rp-cAMP, 50 mM baclofen sup-
pressed the calcium current by 22 6 2% (n 5 24),
about 75% of control. If the internal levels of cAMP
were increased by dialysis then the effect of 100 mM ba-
clofen was reduced by about 50% (19 6 2% suppres-
sion in six cells). Forskolin was superfused onto the ret-
ina, and, therefore, the effect of forskolin on the cal-
cium current could be measured. When ganglion cells
were exposed to forskolin, it produced a 27 6 3% sup-
pression of the calcium current. And in the presence of
forskolin, 50 mM baclofen produced a 15 6 3% reduc-
tion in the calcium current (n 5 11). If baclofen was
acting on calcium channels that were not affected by
forskolin, a suppression of 44% by baclofen would be
anticipated. Therefore, the action of baclofen was sig-
nificantly occluded by forskolin. The results suggest
that activation of the PKA pathway interferes with the
effects of GABAB-BACLOFENR stimulation.
A few antagonists of other second messenger kinase
pathways were tested and found not to alter the action
of baclofen. These included a protein kinase C inhibi-
tor, staurosporine, and a tyrosine kinase inhibitor,
genistein.
The effects of PKA agonists and antagonists suggest a
role for this pathway in mediating the response to ba-
clofen, whereas the prepulse data suggest a direct
G-protein action that is independent of second messen-
gers such as PKA. This discrepancy could be explained
if the PKA system autonomously regulated the ba-
clofen-sensitive calcium channel. Prepulse experiments
supported this proposition (Fig. 10). While the effect
of baclofen was reversed by prepulse facilitation (re-
sponse 2 in Fig. 10), the action of forskolin was unaf-
fected by the prepulse (response 3). In addition, the ef-
fect of baclofen and forskolin together (response 4)
Figure 8. Depolarizing prepulses reduce the effect of baclofen.
Barium currents were elicited by stimulating pulses of 110 mV. If
the conditioning potential was 270 mV, baclofen significantly re-
duced the barium current. But after a conditioning potential of
1100 mV, baclofen had much less effect on the barium current
evoked by the 110 mV pulse.
Figure 9. PKA analogues re-
duce the effect of baclofen.
The top row (A) shows exam-
ples for each of the four agents
tested while the bottom row
(B) graphs the data for all cells
tested. In the top row, trace 1 5
PKA analogue and trace 2 5
baclofen 1 PKA analogue ex-
cept for the forskolin figure,
where trace 1 5 control, trace
2 5 forskolin, and trace 3 5 ba-
clofen plus forskolin.54 Retinal GABA Receptors
was less than the sum of each agent individually. This
indicates that baclofen and forskolin act in parallel to
reduce the calcium channel activation. Forskolin acts
by a mechanism that differs from that produced by
GABAB-BACLOFENR activation, yet occludes the effect of
baclofen.
The action of baclofen was suppressed by calmidazo-
lium, an inhibitor of calcium-calmodulin. In ten gan-
glion cells, internal dialysis with 100 mM calmidazolium
reduced the effect of baclofen by an average of 72%
(Fig. 11 C). Internal dialysis with 100 mM trifluopera-
zine, another calcium-calmodulin inhibitor, reduced
baclofen’s action by 57% (n 5 7). A third inhibitor,
W-7 (100 mM added to pipette), suppressed 43% of the
baclofen effect (n 5 5).
Calcium-calmodulin can activate protein kinases and
phosphatases. We therefore examined the effect of mi-
crocystin LR, an inhibitor of protein phosphatases. An
example is shown in Fig. 11, where 50 mM baclofen
(Fig. 11 A, trace 2) suppressed the control barium cur-
rent (trace 1) by 14% in this cell. Microcystin alone
produced a very small suppression of the barium cur-
rent in the same cell (Fig. 11 B, trace 1). But 50 mM ba-
clofen in the presence of microcystin (trace 2) reduced
the barium current by 29%. In eleven cells tested in
this manner, microcystin enhanced the effect of 50 mM
baclofen by 161% (from a mean calcium current sup-
pression of 23 6 3% to a mean of 37 6 3%). Internal
dialysis of cyclosporin A, a calcineurin phosphatase in-
hibitor, augmented baclofen’s mean effect to 152% of
control (n 5 7). Okadaic acid, another phosphatase in-
hibitor, produced a similar enhancement. While block-
ers of calmodulin-dependent phosphatases had a dra-
matic effect on baclofen’s action, KN-62, a very potent
blocker of some calcium-calmodulin kinases, had only
a slight suppressive effect (data not shown). Internal di-
alysis with 50–100 mM KN-62 reduced the baclofen ef-
fect by 22% (n 5 5).
We did not find any evidence that the calcium-cal-
modulin modulation of the GABABR pathway resulted
from calcium release from internal stores. Neither hep-
arin, a blocker of the IP3 pathway, nor ruthenium red,
a blocker of the ryanodine receptor, reduced the effect
of baclofen (Fig. 11, D and E). Ruthenium red was
tested by placing it in the electrode because extracellu-
lar application significantly reduced membrane barium
currents. In three cells, 50 mM baclofen in the presence
of ruthenium red reduced the barium current by 30 6
5%. Heparin was also included in the patch pipette so-
lution. After heparin dialysis, 50 mM baclofen still re-
duced the barium current by 33 6 1% (n 5 7). This
suppression by 50 mM baclofen, in the presence of ru-
thenium red or heparin is very similar to the average ef-
fect of 50 mM baclofen alone (29 6 1% suppression).
Modulation of CACA-sensitive GABAB Receptors
As noted, internal levels of GTP regulate the CACA-sen-
sitive GABABR. Associated with this observation,
GABAB-CACAR activation was significantly (P , 0.01) en-
hanced by sodium nitroprusside or by 8-bromo-cyclic
GMP, as illustrated in Fig. 12. In these experiments, a
voltage ramp was applied every 30 s and the peak inward
barium current was measured. When 50 mM 8-bromo-
cyclic GMP was superfused on the retinal slice (Fig. 12
A), it produced a modest reduction in the barium cur-
rent. In the presence of 8-bromo-cGMP, 50 mM CACA
produced a large reduction in the HVA barium cur-
rent. After recovery, CACA alone was applied and
caused a smaller reduction in the barium current. In
ten cells, CACA in the presence of 8-bromo-cGMP re-
duced the barium current by 38 6 4%, while CACA
alone suppressed 12 6 2% of this current. The same
experiment was performed in the presence of 20 mM
H-9, a blocker of guanylate kinase. Under these condi-
tions the effect of CACA was not enhanced by 8-bromo-
cGMP (Fig. 12 B). In ten cells, CACA alone suppressed
15 6 3% of the barium current, but in the presence of
H-9 and 8-bromo-cGMP only 11 6 3% of the current
was suppressed. As another control, the retina was su-
perfused with membrane impermeant 100 mM cGMP.
It did not enhance the effect of CACA in any of 16 cells
tested. When the retina was superfused with 300 mM so-
dium nitroprusside, a generator of NO, it also pro-
duced a modest suppression of the peak calcium cur-
rent and it enhanced the effect of CACA (Fig. 12 D). In
seven cells, CACA alone produced a 6 6 1% calcium
current suppression, while in the presence of sodium
nitroprusside CACA suppressed 21 6 6% of the cal-
Figure 10. Prepulse facilitation does not influence the effect of
PKA. The left side of this figure shows that when barium currents
are elicited by stepping to 15 mV from a holding potential of 270
mV (1), baclofen reduces more barium current (2) than does for-
skolin (3). But after a conditioning pulse to 1100 mV, the effect of
forskolin is the same but that of baclofen is suppressed and is now
less than that of forskolin.55 Zhang et al.
cium current. NG-monomethyl-l-arginine, an inhibitor
of nitric oxide synthase, was tested in four ganglion
cells, but alone it did not suppress the effect of CACA
(data not shown). These results indicate that nitric ox-
ide stimulation of cGMP can up-regulate the CACA-
sensitive GABA receptor, but that the NO system is not
endogenously active under the conditions of our exper-
iments.
Figure 11. Calmodulin-depen-
dent  enzymes regulate the
GABAB-BACLOFENR. This figure
shows the effects of baclofen on
barium currents in the pres-
ence of agents that inhibit cal-
cium-calmodulin (Calmidazo-
lium), phosphatases (Microcys-
tin), and internal calcium
release (Heparin and Ruthenium
Red). (A) Baclofen (2) reduces
the barium current. (B) Micro-
cystin alone has little effect on
this barium current (1) (record-
ing from the same cell as in A),
but the effect of baclofen was
enhanced by microcystin (2).
(C) Calmidazolium (1) (added
to whole cell pipette) sup-
pressed the effect of baclofen
(2), while heparin and ruthe-
nium red (both added to whole
cell pipette) did not reduce the
effect of baclofen. The left side
of this figure contains examples
from single ganglion cells while
the right side of the figure
charts the effects on the popula-
tion of neurons examined.
Figure 12. The GABAB-CACAR
pathway is enhanced by nitric
oxide. CACA’s effect was en-
hanced when the retina was su-
perfused with 8-bromo-cGMP
or sodium nitroprusside. In
each graph, the peak voltage-
activated barium current was
measured every 30 s and plot-
ted. (A) While 50 mM 8-bromo-
cGMP slightly reduced the bar-
ium current, 50 mM CACA in
the presence of this second
messenger analogue produced
a much larger decrease in bar-
ium current than when applied
alone (n 5 22). (B) When a
similar experiment was per-
formed with the addition of 20
mM H-9, a cGMP kinase inhibi-
tor, the effect of CACA was not
enhanced (n 5 10). (C) Addi-
tion of the impermeant 100
mM cGMP to the bath did not
increase the CACA effect (n 5
16). (D) When 300 mM sodium
nitroprusside was added to the
superfusate, the effect of CACA
was enhanced (n 5 6).56 Retinal GABA Receptors
discussion
GABA Receptor Diversity in Ganglion Cells
This study reveals that amphibian ganglion cells con-
tain two distinct metabotropic GABA receptors: GABAB-
BACLOFENR and GABAB-CACAR. These neurons also possess
two ionotropic GABA receptors, GABAAR and GABACR,
which regulate chloride conductances (Zhang and
Slaughter, 1995). Although we did not test for all of the
GABARs on each ganglion cell, each receptor subtype
was found on almost all neurons examined, indicating
that most ganglion cells contain all four subtypes. The
GABAAR is a rapid onset, fast desensitizing receptor,
while the GABACR has slower activation kinetics but
shows little desensitization (Qian and Dowling, 1993;
Feigenspan et al., 1993; Amin and Weiss, 1994). There-
fore, the GABAAR may be more influential in phasic in-
hibition while the GABACR may produce more tonic
inhibition. A similar separation of function occurs be-
tween the two metabotropic GABARs. Both down-regu-
late calcium currents, but they affect different types of
calcium channel, they act through different second
messenger pathways, and they are differentially regu-
lated. Furthermore, the GABAB-BACLOFENRs also activate
a small potassium conductance (Slaughter and Bai,
1989; Zhang and Slaughter, personal communication),
while the GABAB-CACARs do not. It fits the premise that
the inhibitory GABAergic input to ganglion cells is
eclectic, allowing a spectrum of inhibitory responses to
the same transmitter. A preliminary report of a similar
diversity of GABA receptors in turtle retinal ganglion
cells (Liu and Lasater, 1994b) suggests this is a general
characteristic of these neurons. As discussed below,
each receptor pathway can be differentially modulated,
indicating that the relative weighting of this panoply of
GABA inhibition is transformable.
Modulation of the GABAB-BACLOFENR Transduction Pathway
The action of GDP-b-S indicates that the GABAB-BACLOFENR
acts through a G-protein pathway (Fig. 7), and prepulse
experiments suggest that a G-protein subunit may di-
rectly modulate the calcium channel (Boland and
Bean, 1993). Forskolin and internal cAMP reduced the
effect of baclofen, but even relatively high doses of
these agents did not eliminate baclofen’s effect. More-
over, the effect of baclofen was reversed by prepulse fa-
cilitation while forskolin’s action was unaltered by this
protocol. Therefore, it is likely that PKA activates a sec-
ond, parallel pathway that independently down-regu-
lates the same channels affected by baclofen.
Blocking of calcium-calmodulin with calmidazolium, tri-
fluoperazine, or W-7 largely suppressed GABAB-BACLOFENR
action. None of these agents alone produced an obvi-
ous alteration in the calcium current. Subtle changes
would be difficult to detect because all drugs were ap-
plied by internal dialysis and therefore were compared
statistically to other neurons that served as a control.
Calcium-calmodulin stimulates a number of pathways,
including specific phosphatases and kinases. KN-62, a
potent blocker of some calcium-calmodulin kinases,
did not suppress the effect of baclofen. Blockers of cal-
cium-calmodulin dependent phosphatases, such as cy-
closporin A and microcystin, enhanced the effect of ba-
clofen. Phosphatase inhibitors did not appear to have a
direct effect on the calcium current, indicating that phos-
phorylation enhanced the GABAB-BACLOFENR pathway.
Thus, calmodulin-dependent phosphatases down-regu-
lated the GABAB-BACLOFENR. But calmodulin antagonists
reduced the effect of baclofen, indicating that calmod-
ulin stimulation is required for GABAB-BACLOFENR activity.
Therefore, another calmodulin pathway must be in-
volved, possibly a calmodulin-dependent kinase. The
ineffectiveness of KN-62 prevents clear identification of
a calmodulin kinase, but the action of H-7 (coupled
with the ineffectiveness of Rp-cAMP) could be inter-
preted as a block of a calmodulin-kinase pathway.
While the precise calmodulin kinase pathway was not
identified, these experiments suggest a regulatory scheme
in which calmodulin modulates the activity of the
GABA receptor by both up-regulation through kinase
Figure 13. A tentative model of the baclofen transduction path-
way. Baclofen reduces the voltage-activated calcium current via a
direct G-protein interaction with N-type calcium channels. Through
a parallel mechanism, the cAMP pathway also reduces current
through this channel. A calcium-calmodulin (Ca/CaM)-depen-
dent kinase (PK) is required for GABAB-BACLOFENR activity. Calmod-
ulin-dependent phosphatases (PP) down-regulate this receptor.
Calcium entry through the N-type channel may activate an auto-
regulatory negative feedback by stimulating the calmodulin kinase.57 Zhang et al.
activation and down-regulation through phosphatase
activation.
A tentative model of GABAB-BACLOFENR transduction
consistent with our data (Fig. 13) proposes that ba-
clofen down-regulates N-type calcium channels through
a direct G-protein pathway. The GABAB-BACLOFENR is bi-
phasically modulated by calmodulin: up-regulation of
the receptor by calmodulin, probably through a kinase,
and down-regulation through a calmodulin-dependent
phosphatase. The balance between these two calmodu-
lin-dependent enzymes would determine the phospho-
rylation state, and therefore the activity, of this trans-
duction pathway. In addition, a parallel PKA pathway
also down-regulates the same population of calcium
channels.
One ramification of the model is that the calcium-
calmodulin system provides a feedback loop between
the calcium channel and the GABAB-BACLOFENR. The
GABAB-BACLOFENR pathway does not appear to require
calcium from internal stores (based on the heparin and
ruthenium red data). Therefore, calcium influx through
the voltage-sensitive calcium channel may stimulate
calmodulin, which up-regulates the GABAB-BACLOFENR.
A check on this negative feedback would be the phos-
phatase system, which turns off the baclofen receptor.
This mechanism could help to regulate the internal cal-
cium concentration. The model implies that the calmod-
ulin activation of kinases and phosphatases have differ-
ent calcium sensitivities or that there is higher gain in
the kinase circuit.
Modulation of GABAB-CACAR Action
Considering the variety of GABA receptors in ganglion
cells, changes in the weighting between different recep-
tors can serve to alter the postsynaptic response to the
same presynaptic GABAergic inputs. Second messen-
gers can modulate each GABA receptor. We found that
internal dialysis with ATP or GTP shifted the relative ef-
fectiveness of the GABAB-BACLOFENR and GABAB-CACAR,
respectively. Related to this effect, 8-bromo-cGMP or so-
dium nitroprusside augmented the effects of CACA ap-
plication. This implies that NO stimulation of guanylate
cyclase can enhance the effectiveness of the GABAB-CACAR-
activated second messenger cascade. However, NO an-
tagonists alone did not decrease the effect of CACA, in-
dicating that NO production was normally low under
the conditions of our experiments. Liepe et al. (1994)
found that many cells in the tiger salamander retina have
the ability to synthesis NO. Amacrine, ganglion, and
Müller cells all have this capability and are positioned
to affect the ganglion cell GABAB-CACAR.
Many regulatory mechanisms also produce differen-
tial effects on ionotropic GABARs. For example, pro-
tein kinase C reduces GABACR and enhances GABAAR
currents (Dong and Werblin, 1994; Feigenspan and
Bormann, 1994; Wellis and Werblin, 1995). Similarly,
low micromolar concentrations of zinc can reduce the
GABACR current but enhance the GABAAR current
(Chappell et al., 1995). Zinc is believed to be synapti-
cally released by photoreceptors (Wu et al., 1993).
Overall, these modulatory mechanisms can be em-
ployed to adjust the balance of inhibitory action pro-
duced by the four GABA receptor subtypes and sug-
gests that the effects of the ionotropic receptors are
complementary, as are the metabotropic receptors.
In summary, the range of GABA receptors found on
ganglion cells coupled with the ability to modulate their
effects extends the processing capabilities at this final
step in the retinal network. Modulation of inhibition can
be a mechanism to shift the balance of weighted inputs
or postsynaptic processing in the retina’s output neurons.
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